Metagenomi, Inc.
MGX
$2.07
$0.136.70%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -6.87% | 76.48% | 28.90% | 121.61% | 151.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.87% | 76.48% | 28.90% | 121.61% | 151.64% |
| Cost of Revenue | -2.16% | 24.86% | 56.18% | 64.41% | 139.04% |
| Gross Profit | -1.85% | 26.73% | -76.76% | -30.59% | -129.24% |
| SG&A Expenses | -3.53% | 29.19% | 35.38% | 24.37% | 73.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.48% | 25.84% | 51.12% | 52.59% | 120.13% |
| Operating Income | 0.05% | 6.12% | -61.85% | -28.10% | -105.89% |
| Income Before Tax | -12.17% | -16.45% | -80.45% | -20.22% | -90.91% |
| Income Tax Expenses | -274.63% | -215.86% | -- | 222.22% | 91.13% |
| Earnings from Continuing Operations | 5.28% | 17.44% | -55.88% | -31.91% | -90.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.28% | 17.44% | -55.88% | -31.91% | -90.93% |
| EBIT | 0.05% | 6.12% | -61.85% | -28.10% | -105.89% |
| EBITDA | 1.05% | 8.25% | -62.36% | -26.24% | -104.54% |
| EPS Basic | 91.23% | 80.86% | 74.89% | -31.91% | -90.55% |
| Normalized Basic EPS | 90.64% | 78.54% | 70.93% | -20.23% | -90.54% |
| EPS Diluted | 91.23% | 80.86% | 74.89% | -31.96% | -90.55% |
| Normalized Diluted EPS | 90.64% | 78.54% | 70.93% | -20.23% | -90.54% |
| Average Basic Shares Outstanding | 979.90% | 331.37% | 520.86% | 0.00% | 0.20% |
| Average Diluted Shares Outstanding | 979.90% | 331.37% | 520.86% | 0.00% | 0.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
